WO2008118626A3 - Inhibitors of jnk and methods for identifying inhibitors of jnk - Google Patents

Inhibitors of jnk and methods for identifying inhibitors of jnk Download PDF

Info

Publication number
WO2008118626A3
WO2008118626A3 PCT/US2008/056341 US2008056341W WO2008118626A3 WO 2008118626 A3 WO2008118626 A3 WO 2008118626A3 US 2008056341 W US2008056341 W US 2008056341W WO 2008118626 A3 WO2008118626 A3 WO 2008118626A3
Authority
WO
WIPO (PCT)
Prior art keywords
jnk
methods
inhibitors
identifying
jip
Prior art date
Application number
PCT/US2008/056341
Other languages
French (fr)
Other versions
WO2008118626A2 (en
WO2008118626A9 (en
Inventor
Maurizio Pellecchia
Original Assignee
Burnham Inst Medical Research
Maurizio Pellecchia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst Medical Research, Maurizio Pellecchia filed Critical Burnham Inst Medical Research
Publication of WO2008118626A2 publication Critical patent/WO2008118626A2/en
Publication of WO2008118626A9 publication Critical patent/WO2008118626A9/en
Publication of WO2008118626A3 publication Critical patent/WO2008118626A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Abstract

The invention provides methods, e.g., screening methods, for identifying modulators of the JNK/JIP interaction. The invention also provides kits comprising reagents for performing the methods of the invention. Also provided are compounds identified as modulators of the JNK/JIP interaction using the disclosed methods, pharmaceutical compositions and therepeutic methods using same.
PCT/US2008/056341 2007-03-08 2008-03-08 Inhibitors of jnk and methods for identifying inhibitors of jnk WO2008118626A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90593307P 2007-03-08 2007-03-08
US60/905,933 2007-03-08
US273607P 2007-11-08 2007-11-08
US61/002,736 2007-11-08

Publications (3)

Publication Number Publication Date
WO2008118626A2 WO2008118626A2 (en) 2008-10-02
WO2008118626A9 WO2008118626A9 (en) 2008-12-18
WO2008118626A3 true WO2008118626A3 (en) 2009-05-07

Family

ID=39789229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056341 WO2008118626A2 (en) 2007-03-08 2008-03-08 Inhibitors of jnk and methods for identifying inhibitors of jnk

Country Status (1)

Country Link
WO (1) WO2008118626A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761335A1 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
MX340997B (en) 2010-08-18 2016-08-03 Samumed Llc Diketones and hydroxyketones as catenin signaling pathway activators.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20151721A1 (en) 2013-02-22 2015-12-07 Samumed Llc Y-DICETONES AS ACTIVATORS OF THE WNT / B-CATENIN SIGNALING ROUTE
KR102165385B1 (en) 2014-08-20 2020-10-15 사뮤메드, 엘엘씨 Gamma-diketones for treatment and prevention of aging skin and wrinkles
GB201514649D0 (en) * 2015-08-18 2015-09-30 Medical Res Council 2-Sulfonylpyrimidines
IL251949A0 (en) 2017-04-26 2017-07-31 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Small organic molecules for use in the treatment neuroinflammatory disorders
MX2021003158A (en) 2018-09-18 2021-07-16 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors.
WO2021050473A1 (en) * 2019-09-10 2021-03-18 Massachusetts Institute Of Technology In silico discovery of effective antimicrobials
WO2023212529A1 (en) * 2022-04-25 2023-11-02 Abs Global, Inc. Compositions and methods for enhancing sperm cell quality

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049188A1 (en) * 1997-04-28 1998-11-05 University Of Massachusetts Inhibitors of the jnk signal transduction pathway and methods of use
US6159731A (en) * 1997-02-12 2000-12-12 Massachusetts Institute Of Technology Daxx, a Fas-binding protein that activates JNK and apoptosis
US20050171338A1 (en) * 2001-01-08 2005-08-04 Steven Dower Mammalian tribbles signaling pathways and methods and reagents related thereto
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006094230A2 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159731A (en) * 1997-02-12 2000-12-12 Massachusetts Institute Of Technology Daxx, a Fas-binding protein that activates JNK and apoptosis
WO1998049188A1 (en) * 1997-04-28 1998-11-05 University Of Massachusetts Inhibitors of the jnk signal transduction pathway and methods of use
US20020119135A1 (en) * 1997-04-28 2002-08-29 Davis Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US20050171338A1 (en) * 2001-01-08 2005-08-04 Steven Dower Mammalian tribbles signaling pathways and methods and reagents related thereto
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006094230A2 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARDWELL, LEE ET AL.: "Signaling in the Yeast Pheromone Response Pathway: Specific and High-Affinity Interaction of the Mitogen-Activated Protein (MAP) Kinases Kss1 and Fus3 with the Upstream MAP Kinase Kinase Ste7.", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, 1996, pages 3638 AND *
HEO, Y.-S. ET AL.: "Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.", THE EMBO JOURNAL., vol. 23, 2004, pages 2186 - 2187 *

Also Published As

Publication number Publication date
WO2008118626A2 (en) 2008-10-02
WO2008118626A9 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
JO2778B1 (en) Certain Compounds, Compositions and Methods
BRPI0608376A8 (en) binding composition, method of using a binding composition, and detection kit
EP1943348A4 (en) Compositions, methods, and kits for amplifying nucleic acids
NO20090047L (en) Anti-DLL4 antibodies and methods for their use
WO2011047087A3 (en) Protein detection via nanoreporters
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2009076676A3 (en) Compositions and methods for producing isoprene
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2008033575A3 (en) Methods of identifying biochemical pathways
DE602006019964D1 (en) CLEANING OF MONTELUKAST
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
EP2101772A4 (en) Intermediate duration neuromuscular blocking agents and antagonists thereof
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2008121506A3 (en) Renin inhibitors
WO2008156610A3 (en) Antibiotic compounds
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
WO2009042270A3 (en) Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
WO2007111982A3 (en) Methods for treating cognitive and other disorders
WO2009120183A3 (en) System for the detection of a biological pathogen and use thereof
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
DE602006021548D1 (en) SPECIMEN LENS AND COATING OF A REACTION SURFACE
WO2009052221A3 (en) Methods for extracting platelets and compositions obtained therefrom
NO20083116L (en) Alumina particles as well as processes for their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799699

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08799699

Country of ref document: EP

Kind code of ref document: A2